Stockscreener 앱 받기
55.89
2.43%
-1.39
전일 마감가:
$57.28
열려 있는:
$57.29
하루 거래량:
1.72M
Relative Volume:
0.84
시가총액:
$5.20B
수익:
$536.20M
순이익/손실:
$-45.64M
주가수익비율:
-104.51
EPS:
-0.5348
순현금흐름:
$-28.94M
1주 성능:
-2.56%
1개월 성능:
-1.62%
6개월 성능:
+79.77%
1년 성능:
+261.75%
1일 변동 폭
$55.30
$57.55
1주일 범위
$54.59
$59.09
52주 변동 폭
$15.03
$60.10
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
55.89 | 5.27B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Travere Therapeutics Inc (TVTX) Institutional Confidence - TradingKey
Travere Therapeutics Inc (TVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Travere Therapeutics Inc (TVTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Travere Therapeutics Inc (TVTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Travere Therapeutics Inc (TVTX) Cash Flow - TradingKey
Investigation launched into Travere Therapeutics' officers for possible self-dealing breaches - Pluang
TVTX|Travere Therapeutics Inc|Price:56.680|Chg%:-0.680 - TradingKey
Travere Therapeutics Inc (TVTX) Income Statement - TradingKey
Travere Therapeutics Inc (TVTX) Balance Sheet - TradingKey
Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup - ChartMill
Travere Therapeutics Inc (TVTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Travere Therapeutics Inc (TVTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
Travere Therapeutics Inc (TVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Travere Therapeutics (TVTX) Gets a Buy from Guggenheim - The Globe and Mail
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.71, Implies 4% Upside - TradingView
TVTX|Travere Therapeutics Inc|Price:56.670|Chg%:+0.410 - TradingKey
Why (TVTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ETFs Investing in Travere Therapeutics, Inc. Stocks - TradingView
RTRX5376243 Bond Profile — Key Metrics - TradingView
Exploring High Growth Tech Stocks In The US For July 2026 - simplywall.st
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Law firm probes Travere Therapeutics officers f... - Pluang
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Pediatrix Medical Group (MD) and Travere Therapeutics (TVTX) - The Globe and Mail
RTRX6388605 Bond Risk Profile - TradingView
RTRX6388605 Bond Profile — Key Metrics - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics Accounting Chief Sandra Calvin to Retire in 2027 - Moomoo
Travere Therapeutics plans accounting leadership transition in 2026 - The Globe and Mail
Travere Therapeutics, Inc. Files Form 8-K with SEC: Key Details on Company and Stock Listing for July 2026 - Minichart
Sandra Calvin to Retire as Travere Therapeutics CAO; John Torell Named Successor - TradingView
Travere Therapeutics (NASDAQ: TVTX) plans CAO transition as Sandra Calvin retires - Stock Titan
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics Inc. (TVTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
US FDA approves Vera's kidney disease drug - Reuters
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib - Macau Business
Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX) - TradingView
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy - AOL.com
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress - AOL.com
Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative? - simplywall.st
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics Receives Notice of Allowance from the U.S. P - The National Law Review
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Understanding Momentum Shifts in (TVTX) - Stock Traders Daily
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Travere Therapeutics Inc 주식 (TVTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Coughlin Timothy | Director |
Jun 12 '26 |
Sale |
50.07 |
10,000 |
500,747 |
56,250 |
| Baynes Roy D. | Director |
Jun 12 '26 |
Option Exercise |
21.38 |
4,500 |
96,210 |
46,000 |
| Baynes Roy D. | Director |
Jun 12 '26 |
Sale |
50.00 |
4,500 |
225,000 |
41,500 |
2.44%
0.02%
자본화:
|
볼륨(24시간):